More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
The Canadian biotech company Nova Mentis Life Science Corp. (OTCQB:NMLSF) is filing new provisional patent applications to the U.S. Patent and Trademark Office (USPTO) in order to protect potential conclusions from its psilocybin preclinical studies as well as its proprietary therapy with psilocybin and psilocybin-based tryptamine derivatives for neuroinflammatory disorders (NID).
這家加拿大生物科技公司Nova Mentis生命科學公司(OTCQB：NMLSF)正在向美國專利委員會提交新的臨時專利申請美國專利商標局(USPTO)為了保護其裸蓋菇素臨牀前研究的潛在結論，以及其使用裸蓋菇素和基於裸蓋菇素的色胺衍生物的專利治療神經炎症性疾病(NID).
NOVA's therapeutic paradigm includes diagnosis, monitoring and treating neuroinflammatory diseases and conditions with psychoactive tryptamine derivatives. Their research program aims to respond to the need for an accurate and effective diagnosis & treatment of NID by generating clinical biomarker data for aberrant gene expression and cellular communication in neurological disease or injury, and by providing insights into possible interventions and disease monitoring.
Nova的治療模式包括診斷、監測和治療神經炎性疾病，以及使用具有精神活性的色胺衍生物治療疾病。他們的研究計劃旨在通過以下方式迴應對NID準確有效診斷和治療的需求神經系統疾病或損傷中異常基因表達和細胞通訊的臨牀生物標誌物數據，並對可能的幹預措施和疾病監測提供見解。
Dr. Marvin S. Hausman MD, chairman of NOVA's Scientific Advisory Board, affirmed that the current patent application filing represents a "major milestone" in their psilocybin research program.
馬文·S·豪斯曼博士，Nova科學顧問委員會主席，肯定了目前的專利申請是他們裸蓋菇素研究計劃的一個重要里程碑。
"The company is now in a position to reveal the breakthrough preclinical psilocybin results uncovered in its treatment of fragile X syndrome (FXS)," Hausman said. "Oral repetitive doses of microdose psilocybin showed a more robust improvement in memory than the same doses given by injection. Metabolic changes of psilocybin within the small intestine and perhaps the microbiome may represent a new paradigm in the application of psilocybin to the treatment of autism spectrum disorder (ASD)."
豪斯曼説：“該公司現在能夠公佈在其治療脆性X綜合徵(FXS)中發現的突破性臨牀前裸蓋菇素結果。”“口服重複劑量的裸蓋菇素比注射相同劑量的裸蓋菇素能更有效地改善記憶。裸蓋菇素在小腸和微生物體內的代謝變化可能代表了裸蓋菇素在自閉症譜系障礙(ASD)治療中的應用的新範例。”
As stated by the company, the psilocybin formulation was evaluated in two distinct rat models of autism in the laboratory of Dr. Viviana Trezza in Italy, and demonstrated psilocybin proof of efficacy and safety. In February, NOVA announced it had successfully completed its preclinical study which confirmed oral microdose psilocybin as a potential treatment option for ASD and FXS.
正如該公司所説，裸蓋菇素製劑在兩種不同的自閉症大鼠模型上進行了評估。Viviana Trezza博士在意大利，並證明瞭裸蓋菇素的有效性和安全性。在2月份，Nova宣佈已成功完成其臨牀前研究，證實口服微劑量裸蓋菇素是一種潛在的ASD和FXS的治療選擇.
The February research found that a repeated low dose of the proprietary psilocybin drug NM-1001 significantly modulated behavioral and cognitive defects such as recognition memory in a genetic model of FXS. The conclusive data from the study will be presented at the 18th NFXF International Fragile X Conference later this year.
二月份的研究發現，反覆服用低劑量的專有裸蓋菇素藥物NM-1001在FXS的遺傳模型中，顯著調節了行為和認知缺陷，如識別記憶。這項研究的決定性數據將在今年晚些時候舉行的第18屆NFXF國際脆性X大會上公佈。
The fact is that NOVA keeps strengthening its intellectual property by presenting provisional patent applications to protect data from a number of trials recently.
事實是，Nova通過提交臨時專利申請來保護數據免受最近幾次審判的影響，從而不斷加強其知識產權。
Previously, the company had filed provisional patent applications for the following: a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin, and a diagnostic/therapeutic combination of mRNA molecules that encodes proteins involved in the development of the neurodegenerative diseases FXS and ASD.
此前，該公司已經提交了以下臨時專利申請：專有製造工藝用於生產裸蓋菇素和色胺類似物，巴氏囊藻毒素和銅綠假單胞菌，以及信使核糖核酸分子的診斷/治療組合它編碼與神經退行性疾病FXS和ASD發展有關的蛋白質。
The conclusive data from NOVA's most recent study will be presented at the 18th NFXF International Fragile X Conference later this year.
NOVA最新研究的決定性數據將在今年晚些時候舉行的第18屆NFXF國際脆性X大會上公佈。
Photo Courtesy of Pexels.
照片由Pexels提供。
譯文內容由第三人軟體翻譯。